NFKB1 and COVID-19: Even though the pathogenesis of CRS remains not well understood, the involvement of NF-κB activation in production of various inflammatory cytokines was demonstrated by numerous evidences, supporting NF-κB pathway as a potential target for the treatment of critical stage COVID-19 patients (Kircheis et al., 2020).